JP2015508760A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2015508760A5 JP2015508760A5 JP2014556826A JP2014556826A JP2015508760A5 JP 2015508760 A5 JP2015508760 A5 JP 2015508760A5 JP 2014556826 A JP2014556826 A JP 2014556826A JP 2014556826 A JP2014556826 A JP 2014556826A JP 2015508760 A5 JP2015508760 A5 JP 2015508760A5
- Authority
- JP
- Japan
- Prior art keywords
- paracrine
- vector
- nucleic acid
- gene
- cell
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 108090000623 proteins and genes Proteins 0.000 claims description 131
- 230000003076 paracrine Effects 0.000 claims description 124
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 115
- 150000007523 nucleic acids Chemical class 0.000 claims description 109
- 102000005630 Urocortins Human genes 0.000 claims description 106
- 108010059705 Urocortins Proteins 0.000 claims description 106
- 239000000777 urocortin Substances 0.000 claims description 106
- 108020004707 nucleic acids Proteins 0.000 claims description 105
- 102000039446 nucleic acids Human genes 0.000 claims description 105
- 239000013598 vector Substances 0.000 claims description 92
- 210000004027 cell Anatomy 0.000 claims description 89
- 238000002347 injection Methods 0.000 claims description 74
- 239000007924 injection Substances 0.000 claims description 74
- ZEBBPGHOLWPSGI-KPLDDXDLSA-N urocortin ii Chemical compound CC[C@H](C)[C@H](N)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](C(C)C)C(=O)N1CCC[C@H]1C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](C)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@H](C(=O)N[C@@H](CS)C(N)=O)CC1=CN=CN1 ZEBBPGHOLWPSGI-KPLDDXDLSA-N 0.000 claims description 71
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 66
- 229920001184 polypeptide Polymers 0.000 claims description 63
- 239000000203 mixture Substances 0.000 claims description 57
- 241000700605 Viruses Species 0.000 claims description 47
- 239000003981 vehicle Substances 0.000 claims description 45
- 238000000034 method Methods 0.000 claims description 40
- 239000002245 particle Substances 0.000 claims description 29
- 238000001361 intraarterial administration Methods 0.000 claims description 28
- 230000022532 regulation of transcription, DNA-dependent Effects 0.000 claims description 27
- 238000007918 intramuscular administration Methods 0.000 claims description 26
- 238000007920 subcutaneous administration Methods 0.000 claims description 26
- 238000001990 intravenous administration Methods 0.000 claims description 23
- 102000004169 proteins and genes Human genes 0.000 claims description 23
- 201000010099 disease Diseases 0.000 claims description 19
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 19
- 239000012190 activator Substances 0.000 claims description 18
- 206010007559 Cardiac failure congestive Diseases 0.000 claims description 16
- 206010019280 Heart failures Diseases 0.000 claims description 16
- FCENQCVTLJEGOT-KIHVXQRMSA-N stresscopin Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)CC)C(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCSC)NC(=O)[C@@H](NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@@H](N)CC=1C=CC=CC=1)[C@@H](C)O)C(C)C)[C@@H](C)O)[C@@H](C)CC)[C@@H](C)CC)C1=CN=CN1 FCENQCVTLJEGOT-KIHVXQRMSA-N 0.000 claims description 16
- 206010028980 Neoplasm Diseases 0.000 claims description 14
- 230000004064 dysfunction Effects 0.000 claims description 14
- 210000001519 tissue Anatomy 0.000 claims description 14
- 101001091088 Homo sapiens Prorelaxin H2 Proteins 0.000 claims description 12
- 102100034949 Prorelaxin H2 Human genes 0.000 claims description 12
- 239000000443 aerosol Substances 0.000 claims description 12
- 239000007943 implant Substances 0.000 claims description 12
- 230000001965 increasing effect Effects 0.000 claims description 12
- 230000001939 inductive effect Effects 0.000 claims description 12
- 238000007913 intrathecal administration Methods 0.000 claims description 12
- 210000000056 organ Anatomy 0.000 claims description 12
- 230000001105 regulatory effect Effects 0.000 claims description 12
- 238000001727 in vivo Methods 0.000 claims description 11
- 239000002502 liposome Substances 0.000 claims description 11
- 239000002105 nanoparticle Substances 0.000 claims description 11
- 102400000667 Brain natriuretic peptide 32 Human genes 0.000 claims description 10
- 101800000407 Brain natriuretic peptide 32 Proteins 0.000 claims description 10
- 101800002247 Brain natriuretic peptide 45 Proteins 0.000 claims description 10
- 102000015846 Prostacyclin synthases Human genes 0.000 claims description 10
- 201000011510 cancer Diseases 0.000 claims description 10
- 210000000234 capsid Anatomy 0.000 claims description 10
- HPNRHPKXQZSDFX-OAQDCNSJSA-N nesiritide Chemical compound C([C@H]1C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CSSC[C@@H](C(=O)N1)NC(=O)CNC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](CCSC)NC(=O)[C@H](CCCCN)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](N)CO)C(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1N=CNC=1)C(O)=O)=O)[C@@H](C)CC)C1=CC=CC=C1 HPNRHPKXQZSDFX-OAQDCNSJSA-N 0.000 claims description 10
- 108010064377 prostacyclin synthetase Proteins 0.000 claims description 10
- 208000015181 infectious disease Diseases 0.000 claims description 9
- 108010051696 Growth Hormone Proteins 0.000 claims description 8
- 102100038803 Somatotropin Human genes 0.000 claims description 8
- 101150084279 TM gene Proteins 0.000 claims description 8
- 230000003177 cardiotonic effect Effects 0.000 claims description 8
- 239000003102 growth factor Substances 0.000 claims description 8
- 239000000122 growth hormone Substances 0.000 claims description 8
- DTLOVISJEFBXLX-REAFJZEQSA-N relexan 2 Chemical compound C([C@H]1C(=O)N[C@H](C(=O)NCC(=O)N[C@H]2CSSC[C@@H](C(=O)N[C@H](C(N1)=O)CSSC[C@@H](C(NCC(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@H](C(=O)N[C@@H](C)C(=O)N[C@H](C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCCN)NC(=O)[C@H]([C@@H](C)O)NC2=O)C(O)=O)C(=O)NCC(=O)N[C@@H](CCSC)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CO)C(O)=O)[C@@H](C)CC)[C@@H](C)CC)C(C)C)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCSC)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(O)=O)C(C)C)[C@@H](C)CC)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]1NC(=O)CC1)C(C)C)C1=CN=CN1 DTLOVISJEFBXLX-REAFJZEQSA-N 0.000 claims description 8
- 229960002792 serelaxin Drugs 0.000 claims description 8
- 230000002459 sustained effect Effects 0.000 claims description 8
- 210000004556 brain Anatomy 0.000 claims description 7
- 239000012530 fluid Substances 0.000 claims description 7
- 241001164825 Adeno-associated virus - 8 Species 0.000 claims description 6
- 241000702421 Dependoparvovirus Species 0.000 claims description 6
- 206010018429 Glucose tolerance impaired Diseases 0.000 claims description 6
- 208000008589 Obesity Diseases 0.000 claims description 6
- 208000001280 Prediabetic State Diseases 0.000 claims description 6
- 235000019789 appetite Nutrition 0.000 claims description 6
- 239000008280 blood Substances 0.000 claims description 6
- 210000004369 blood Anatomy 0.000 claims description 6
- 206010012601 diabetes mellitus Diseases 0.000 claims description 6
- 235000020824 obesity Nutrition 0.000 claims description 6
- 201000009104 prediabetes syndrome Diseases 0.000 claims description 6
- 208000002815 pulmonary hypertension Diseases 0.000 claims description 6
- 230000002103 transcriptional effect Effects 0.000 claims description 6
- 230000004584 weight gain Effects 0.000 claims description 6
- 235000019786 weight gain Nutrition 0.000 claims description 6
- 230000004580 weight loss Effects 0.000 claims description 6
- 208000014644 Brain disease Diseases 0.000 claims description 5
- 102100022641 Coagulation factor IX Human genes 0.000 claims description 5
- 208000031220 Hemophilia Diseases 0.000 claims description 5
- 208000009292 Hemophilia A Diseases 0.000 claims description 5
- 230000006907 apoptotic process Effects 0.000 claims description 5
- 230000036528 appetite Effects 0.000 claims description 5
- 210000002216 heart Anatomy 0.000 claims description 5
- 208000009429 hemophilia B Diseases 0.000 claims description 5
- 208000017169 kidney disease Diseases 0.000 claims description 5
- 210000004185 liver Anatomy 0.000 claims description 5
- 210000004072 lung Anatomy 0.000 claims description 5
- 210000003205 muscle Anatomy 0.000 claims description 5
- 210000005036 nerve Anatomy 0.000 claims description 5
- 239000000816 peptidomimetic Substances 0.000 claims description 5
- 210000003491 skin Anatomy 0.000 claims description 5
- 230000004936 stimulating effect Effects 0.000 claims description 5
- 241001634120 Adeno-associated virus - 5 Species 0.000 claims description 4
- 241000972680 Adeno-associated virus - 6 Species 0.000 claims description 4
- 241000283690 Bos taurus Species 0.000 claims description 4
- 241000283707 Capra Species 0.000 claims description 4
- 241000700199 Cavia porcellus Species 0.000 claims description 4
- 241000282693 Cercopithecidae Species 0.000 claims description 4
- 241000699800 Cricetinae Species 0.000 claims description 4
- 108010074864 Factor XI Proteins 0.000 claims description 4
- 241000282326 Felis catus Species 0.000 claims description 4
- 101000599951 Homo sapiens Insulin-like growth factor I Proteins 0.000 claims description 4
- 102100037852 Insulin-like growth factor I Human genes 0.000 claims description 4
- 241000282560 Macaca mulatta Species 0.000 claims description 4
- 241000283973 Oryctolagus cuniculus Species 0.000 claims description 4
- 241001494479 Pecora Species 0.000 claims description 4
- 230000015572 biosynthetic process Effects 0.000 claims description 4
- 208000035269 cancer or benign tumor Diseases 0.000 claims description 4
- 230000009787 cardiac fibrosis Effects 0.000 claims description 4
- 210000004413 cardiac myocyte Anatomy 0.000 claims description 4
- 210000004748 cultured cell Anatomy 0.000 claims description 4
- 229960003722 doxycycline Drugs 0.000 claims description 4
- XQTWDDCIUJNLTR-CVHRZJFOSA-N doxycycline monohydrate Chemical compound O.O=C1C2=C(O)C=CC=C2[C@H](C)[C@@H]2C1=C(O)[C@]1(O)C(=O)C(C(N)=O)=C(O)[C@@H](N(C)C)[C@@H]1[C@H]2O XQTWDDCIUJNLTR-CVHRZJFOSA-N 0.000 claims description 4
- 210000002064 heart cell Anatomy 0.000 claims description 4
- 238000000338 in vitro Methods 0.000 claims description 4
- 230000000977 initiatory effect Effects 0.000 claims description 4
- 230000002608 insulinlike Effects 0.000 claims description 4
- 210000004962 mammalian cell Anatomy 0.000 claims description 4
- 239000000126 substance Substances 0.000 claims description 4
- 238000003786 synthesis reaction Methods 0.000 claims description 4
- 230000010247 heart contraction Effects 0.000 claims description 3
- 230000001124 posttranscriptional effect Effects 0.000 claims description 3
- 241000282412 Homo Species 0.000 claims description 2
- 101000687346 Homo sapiens PR domain zinc finger protein 2 Proteins 0.000 claims description 2
- 102100024885 PR domain zinc finger protein 2 Human genes 0.000 claims description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 2
- 108091023040 Transcription factor Proteins 0.000 claims description 2
- 102000040945 Transcription factor Human genes 0.000 claims description 2
- 230000004913 activation Effects 0.000 claims description 2
- 230000000747 cardiac effect Effects 0.000 claims description 2
- 238000006243 chemical reaction Methods 0.000 claims description 2
- 239000003814 drug Substances 0.000 claims description 2
- 238000009472 formulation Methods 0.000 claims description 2
- 239000000499 gel Substances 0.000 claims description 2
- 239000000017 hydrogel Substances 0.000 claims description 2
- 230000002401 inhibitory effect Effects 0.000 claims description 2
- 239000007788 liquid Substances 0.000 claims description 2
- 238000012986 modification Methods 0.000 claims description 2
- 230000004048 modification Effects 0.000 claims description 2
- 229940127249 oral antibiotic Drugs 0.000 claims description 2
- 239000000843 powder Substances 0.000 claims description 2
- ZAHRKKWIAAJSAO-UHFFFAOYSA-N rapamycin Natural products COCC(O)C(=C/C(C)C(=O)CC(OC(=O)C1CCCCN1C(=O)C(=O)C2(O)OC(CC(OC)C(=CC=CC=CC(C)CC(C)C(=O)C)C)CCC2C)C(C)CC3CCC(O)C(C3)OC)C ZAHRKKWIAAJSAO-UHFFFAOYSA-N 0.000 claims description 2
- 229960002930 sirolimus Drugs 0.000 claims description 2
- QFJCIRLUMZQUOT-HPLJOQBZSA-N sirolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 QFJCIRLUMZQUOT-HPLJOQBZSA-N 0.000 claims description 2
- 239000011780 sodium chloride Substances 0.000 claims description 2
- 238000001179 sorption measurement Methods 0.000 claims description 2
- 230000001839 systemic circulation Effects 0.000 claims description 2
- 230000008685 targeting Effects 0.000 claims description 2
- 239000013607 AAV vector Substances 0.000 claims 4
- 108091028043 Nucleic acid sequence Proteins 0.000 claims 4
- 230000000638 stimulation Effects 0.000 claims 4
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims 2
- 230000000694 effects Effects 0.000 claims 2
- 210000005260 human cell Anatomy 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- 229910052708 sodium Inorganic materials 0.000 claims 2
- 239000011734 sodium Substances 0.000 claims 2
- 238000013518 transcription Methods 0.000 claims 2
- 230000035897 transcription Effects 0.000 claims 2
- 206010071436 Systolic dysfunction Diseases 0.000 claims 1
- 230000003213 activating effect Effects 0.000 claims 1
- 230000004596 appetite loss Effects 0.000 claims 1
- 230000017531 blood circulation Effects 0.000 claims 1
- 230000005764 inhibitory process Effects 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 230000000069 prophylactic effect Effects 0.000 claims 1
- 230000001681 protective effect Effects 0.000 claims 1
- 230000004044 response Effects 0.000 claims 1
- XZPMQCKVOWVETG-UHFFFAOYSA-J tetrasodium;2-[(3-carboxylato-3-sulfonatopropanoyl)-octadecylamino]butanedioate Chemical compound [Na+].[Na+].[Na+].[Na+].CCCCCCCCCCCCCCCCCCN(C(CC([O-])=O)C([O-])=O)C(=O)CC(C([O-])=O)S([O-])(=O)=O XZPMQCKVOWVETG-UHFFFAOYSA-J 0.000 claims 1
- 208000031229 Cardiomyopathies Diseases 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- YXLIYGUJLJFLJH-UHFFFAOYSA-L disodium;4-(octadecylamino)-4-oxo-2-sulfonatobutanoate Chemical compound [Na+].[Na+].CCCCCCCCCCCCCCCCCCNC(=O)CC(C([O-])=O)S([O-])(=O)=O YXLIYGUJLJFLJH-UHFFFAOYSA-L 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261598772P | 2012-02-14 | 2012-02-14 | |
| US61/598,772 | 2012-02-14 | ||
| PCT/US2013/025997 WO2013123094A2 (en) | 2012-02-14 | 2013-02-13 | Systemic delivery and regulated expression of paracrine genes for cardiovascular diseases and other conditions |
Related Child Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017163244A Division JP2017203048A (ja) | 2012-02-14 | 2017-08-28 | 心血管疾患および他の状態のためのパラクリン遺伝子の全身送達および制御された発現 |
| JP2019096752A Division JP2019135263A (ja) | 2012-02-14 | 2019-05-23 | 心血管疾患および他の状態のためのパラクリン遺伝子の全身送達および制御された発現 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2015508760A JP2015508760A (ja) | 2015-03-23 |
| JP2015508760A5 true JP2015508760A5 (enExample) | 2016-03-31 |
| JP6562632B2 JP6562632B2 (ja) | 2019-08-21 |
Family
ID=48984885
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014556826A Active JP6562632B2 (ja) | 2012-02-14 | 2013-02-13 | 心血管疾患および他の状態のためのパラクリン遺伝子の全身送達および制御された発現 |
| JP2017163244A Pending JP2017203048A (ja) | 2012-02-14 | 2017-08-28 | 心血管疾患および他の状態のためのパラクリン遺伝子の全身送達および制御された発現 |
| JP2019096752A Withdrawn JP2019135263A (ja) | 2012-02-14 | 2019-05-23 | 心血管疾患および他の状態のためのパラクリン遺伝子の全身送達および制御された発現 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017163244A Pending JP2017203048A (ja) | 2012-02-14 | 2017-08-28 | 心血管疾患および他の状態のためのパラクリン遺伝子の全身送達および制御された発現 |
| JP2019096752A Withdrawn JP2019135263A (ja) | 2012-02-14 | 2019-05-23 | 心血管疾患および他の状態のためのパラクリン遺伝子の全身送達および制御された発現 |
Country Status (18)
| Country | Link |
|---|---|
| US (3) | US20150118287A1 (enExample) |
| EP (2) | EP2814513B1 (enExample) |
| JP (3) | JP6562632B2 (enExample) |
| KR (1) | KR102107482B1 (enExample) |
| CN (2) | CN104220098B (enExample) |
| AU (2) | AU2013221615B2 (enExample) |
| BR (1) | BR112014020127A2 (enExample) |
| CA (1) | CA2864100A1 (enExample) |
| DK (1) | DK2814513T3 (enExample) |
| ES (1) | ES2660492T3 (enExample) |
| HK (1) | HK1254639A1 (enExample) |
| HU (1) | HUE036640T2 (enExample) |
| IL (3) | IL234007A0 (enExample) |
| IN (1) | IN2014DN06789A (enExample) |
| PL (1) | PL2814513T3 (enExample) |
| PT (1) | PT2814513T (enExample) |
| RU (1) | RU2642605C2 (enExample) |
| WO (1) | WO2013123094A2 (enExample) |
Families Citing this family (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8734809B2 (en) | 2009-05-28 | 2014-05-27 | University Of Massachusetts | AAV's and uses thereof |
| EP2814513B1 (en) * | 2012-02-14 | 2017-12-20 | The Regents of The University of California | Systemic delivery and regulated expression of paracrine genes for cardiovascular diseases and other conditions |
| CN106456803A (zh) * | 2014-04-03 | 2017-02-22 | 加利福尼亚大学董事会 | 编码尿皮质素‑2和相关基因的病毒载体的全身递送以治疗糖尿病相关性心脏功能障碍和充血性心力衰竭 |
| US10577627B2 (en) | 2014-06-09 | 2020-03-03 | Voyager Therapeutics, Inc. | Chimeric capsids |
| WO2016065001A1 (en) * | 2014-10-21 | 2016-04-28 | University Of Massachusetts | Recombinant aav variants and uses thereof |
| WO2016073693A2 (en) | 2014-11-05 | 2016-05-12 | Voyager Therapeutics, Inc. | Aadc polynucleotides for the treatment of parkinson's disease |
| CA2975583A1 (en) | 2014-11-14 | 2016-05-19 | Voyager Therapeutics, Inc. | Modulatory polynucleotides |
| CN114717264A (zh) | 2014-11-14 | 2022-07-08 | 沃雅戈治疗公司 | 治疗肌萎缩性侧索硬化(als)的组合物和方法 |
| US11697825B2 (en) | 2014-12-12 | 2023-07-11 | Voyager Therapeutics, Inc. | Compositions and methods for the production of scAAV |
| CN107531752B (zh) * | 2015-05-12 | 2022-05-10 | 加利福尼亚大学董事会 | 用于炎症和纤维化的肽治疗 |
| CN113999875A (zh) * | 2015-05-28 | 2022-02-01 | 康奈尔大学 | 腺相关病毒介导的c1ei递送作为用于血管性水肿的疗法 |
| EP3448874A4 (en) | 2016-04-29 | 2020-04-22 | Voyager Therapeutics, Inc. | COMPOSITIONS FOR TREATING A DISEASE |
| US11299751B2 (en) | 2016-04-29 | 2022-04-12 | Voyager Therapeutics, Inc. | Compositions for the treatment of disease |
| SG11201809643UA (en) | 2016-05-18 | 2018-12-28 | Voyager Therapeutics Inc | Compositions and methods of treating huntington's disease |
| IL262784B2 (en) | 2016-05-18 | 2023-10-01 | Voyager Therapeutics Inc | modulatory polynucleotides |
| WO2018044933A1 (en) | 2016-08-30 | 2018-03-08 | The Regents Of The University Of California | Methods for biomedical targeting and delivery and devices and systems for practicing the same |
| AU2017341849B2 (en) | 2016-10-13 | 2024-03-21 | University Of Massachusetts | AAV capsid designs |
| CN110475573A (zh) * | 2017-01-23 | 2019-11-19 | 新泽西鲁特格斯州立大学 | 用于减少肌脂蛋白表达以及预防和治疗肌营养不良症和心肌病的组合物及其使用方法 |
| KR102182957B1 (ko) | 2017-02-28 | 2020-11-27 | 진메디신 주식회사 | 종양 특이적 살상 아데노바이러스 및 면역 관문 억제제를 포함하는 항암용 조성물 |
| MX2019013172A (es) | 2017-05-05 | 2020-09-07 | Voyager Therapeutics Inc | Composiciones y metodos para tratar la enfermedad de huntington. |
| WO2018204786A1 (en) | 2017-05-05 | 2018-11-08 | Voyager Therapeutics, Inc. | Compositions and methods of treating amyotrophic lateral sclerosis (als) |
| JOP20190269A1 (ar) | 2017-06-15 | 2019-11-20 | Voyager Therapeutics Inc | بولي نوكليوتيدات aadc لعلاج مرض باركنسون |
| JP7229989B2 (ja) | 2017-07-17 | 2023-02-28 | ボイジャー セラピューティクス インコーポレイテッド | 軌道アレイガイドシステム |
| US11760987B2 (en) | 2017-09-07 | 2023-09-19 | The Regents Of The University Of California | Compositions and methods for the treatment or prevention of heart failure |
| MX2020003042A (es) | 2017-09-29 | 2020-11-18 | Voyager Therapeutics Inc | Rescate del fenotipo neurológico central y periférico de la ataxia de friedreich mediante administración intravenosa. |
| US11434502B2 (en) | 2017-10-16 | 2022-09-06 | Voyager Therapeutics, Inc. | Treatment of amyotrophic lateral sclerosis (ALS) |
| WO2019079242A1 (en) | 2017-10-16 | 2019-04-25 | Voyager Therapeutics, Inc. | TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS (ALS) |
| EP3794126A1 (en) | 2018-05-15 | 2021-03-24 | Voyager Therapeutics, Inc. | Compositions and methods for the treatment of parkinson's disease |
| CN112367971A (zh) * | 2018-06-11 | 2021-02-12 | 加利福尼亚大学董事会 | 用以治疗眼睛疾病的脱甲基化 |
| SG11202103151RA (en) | 2018-09-28 | 2021-04-29 | Voyager Therapeutics Inc | Frataxin expression constructs having engineered promoters and methods of use thereof |
| JP7460850B2 (ja) * | 2020-06-12 | 2024-04-02 | ジェンセルメッド インコーポレイテッド | 多重標的化組換えヘルペスシンプルレックスウイルス及びその用途 |
| CN112826823B (zh) * | 2021-01-11 | 2022-03-08 | 中国人民解放军军事科学院军事医学研究院 | 多西环素在制备治疗和/或预防和/或缓解和/或改善心肌病药物中的应用 |
Family Cites Families (61)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4458066A (en) | 1980-02-29 | 1984-07-03 | University Patents, Inc. | Process for preparing polynucleotides |
| US5217879A (en) | 1989-01-12 | 1993-06-08 | Washington University | Infectious Sindbis virus vectors |
| US5733542A (en) | 1990-11-16 | 1998-03-31 | Haynesworth; Stephen E. | Enhancing bone marrow engraftment using MSCS |
| US5270192A (en) | 1991-02-07 | 1993-12-14 | Monsanto Company | Biological artificial liver |
| US5846743A (en) | 1995-02-22 | 1998-12-08 | Brigham And Women's Hospital, Inc. | Polyphoshoinositide binding peptides for intracellular drug delivery |
| US7361332B2 (en) | 1995-03-17 | 2008-04-22 | The Regents Of The University Of California | Treating tumors using implants comprising combinations of allogeneic cells |
| US6214797B1 (en) * | 1995-06-13 | 2001-04-10 | The Salk Institute For Biological Studies | Urocortin peptides, nucleic acid encoding same methods for using same |
| US5721118A (en) | 1995-10-31 | 1998-02-24 | The Regents Of The University Of California, San Diego | Mammalian artificial chromosomes and methods of using same |
| PT876165E (pt) | 1995-12-18 | 2006-10-31 | Angiotech Biomaterials Corp | Composicoes de polimeros reticulados e processos para a sua utilizacao |
| US6025155A (en) | 1996-04-10 | 2000-02-15 | Chromos Molecular Systems, Inc. | Artificial chromosomes, uses thereof and methods for preparing artificial chromosomes |
| US6933331B2 (en) | 1998-05-22 | 2005-08-23 | Nanoproducts Corporation | Nanotechnology for drug delivery, contrast agents and biomedical implants |
| US5874268A (en) | 1996-09-23 | 1999-02-23 | Duke University | Method of introducing exogenous compounds into cells by electroporation and apparatus for same |
| PL189744B1 (pl) * | 1996-11-01 | 2005-09-30 | Eurogene Ltd | Zastosowanie środka będącego białkiem VEGF oraz wszczep do stosowania leczniczego |
| US6630137B1 (en) | 1997-04-28 | 2003-10-07 | Eli Lilly And Company | Activated protein C formulations |
| KR20070005030A (ko) * | 1997-05-06 | 2007-01-09 | 더 리젠츠 오브 더 유니버시티 오브 캘리포니아 | 혈관형성성 트랜스유전자의 생체내 송달에 의한 심장 질환및 심실 리모델링을 치료하기 위한 방법 및 조성물 |
| US20050095227A1 (en) * | 1997-07-22 | 2005-05-05 | The General Hospital Corporation | Treating heart failure |
| SE9704076D0 (sv) | 1997-11-06 | 1997-11-06 | Holdingbolaget Vid Goeteborgs | Method for permeabilisation of cell structures and use thereof |
| US6886568B2 (en) | 1998-04-08 | 2005-05-03 | The Johns Hopkins University | Method for fabricating cell-containing implants |
| AU762220B2 (en) * | 1998-05-28 | 2003-06-19 | Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The | AAV5 vector and uses thereof |
| US6589503B1 (en) | 1998-06-20 | 2003-07-08 | Washington University | Membrane-permeant peptide complexes for medical imaging, diagnostics, and pharmaceutical therapy |
| US6958212B1 (en) | 1999-02-01 | 2005-10-25 | Eidgenossische Technische Hochschule Zurich | Conjugate addition reactions for the controlled delivery of pharmaceutically active compounds |
| EP1225921A1 (en) * | 1999-11-05 | 2002-07-31 | The Regents of the University of California | TECHNIQUES AND COMPOSITIONS FOR TREATING CARDIOVASCULAR DISEASE BY i IN VIVO /i GENE DELIVERY |
| EP1255822A2 (en) * | 1999-12-27 | 2002-11-13 | The Regents Of The University Of California | Modified adenylylcyclase type vi useful in gene therapy for congestive heart failure |
| AU5523701A (en) | 2000-04-06 | 2001-10-23 | Wayne P Franco | Methods of using growth factors for treating heart disease |
| US7442390B2 (en) | 2000-06-05 | 2008-10-28 | University Of South Florida | Method for enhancing engraftment of cells using mesenchymal progenitor cells |
| NZ523803A (en) * | 2000-08-04 | 2004-08-27 | Res Dev Foundation | Human urocortin-related polypeptide (URP) and uses thereof to rreat a pathophysiological state, eg stress, anxiety and appetite dysfunction |
| AU2001284683B2 (en) * | 2000-08-04 | 2006-04-27 | Research Development Foundation | Urocortin proteins and uses thereof |
| JPWO2002088332A1 (ja) | 2001-04-24 | 2004-08-19 | 北海道ティー・エル・オー株式会社 | 小型肝細胞高含有コロニー、その調製方法、その肝組織への成熟化方法、成熟化した小型肝細胞高含有コロニーを用いた薬物機能の推定方法 |
| JP4810062B2 (ja) * | 2001-12-17 | 2011-11-09 | ザ・トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・ペンシルベニア | アデノ随伴ウイルス（ａａｖ）血清型８の配列 |
| US6936585B2 (en) * | 2002-01-16 | 2005-08-30 | The Procter & Gamble Company | Corticotropin releasing factor 2 receptor agonists |
| US7166133B2 (en) | 2002-06-13 | 2007-01-23 | Kensey Nash Corporation | Devices and methods for treating defects in the tissue of a living being |
| US20040151766A1 (en) | 2003-01-30 | 2004-08-05 | Monahan Sean D. | Protein and peptide delivery to mammalian cells in vitro |
| US7241455B2 (en) | 2003-04-08 | 2007-07-10 | Boston Scientific Scimed, Inc. | Implantable or insertable medical devices containing radiation-crosslinked polymer for controlled delivery of a therapeutic agent |
| EP1648298A4 (en) | 2003-07-25 | 2010-01-13 | Dexcom Inc | OXYGEN-IMPROVED MEMBRANE SYSTEMS FOR IMPLANTABLE DEVICES |
| US7794706B2 (en) | 2003-10-14 | 2010-09-14 | Medivas, Llc | Bioactive wound dressings and implantable devices and methods of use |
| WO2005063156A1 (en) | 2003-12-22 | 2005-07-14 | Shear/Kershman Laboratories, Inc. | Oral peptide delivery system with improved bioavailability |
| CN1917859A (zh) | 2003-12-24 | 2007-02-21 | 日本株式会社Ltt生物医药 | 载药纳米微粒及其制备方法以及含有该纳米微粒的非肠道给药用制剂 |
| US20050244463A1 (en) | 2004-04-30 | 2005-11-03 | Allergan, Inc. | Sustained release intraocular implants and methods for treating ocular vasculopathies |
| US8658203B2 (en) | 2004-05-03 | 2014-02-25 | Merrimack Pharmaceuticals, Inc. | Liposomes useful for drug delivery to the brain |
| WO2006014035A1 (en) | 2004-08-06 | 2006-02-09 | Biospectrum, Inc. | Multiple layered liposome and preparation method thereof |
| CA2569736A1 (en) | 2004-08-20 | 2006-03-02 | Russell Anderson | Methods of administering microparticles combined with autologous body components |
| US7919112B2 (en) | 2004-08-26 | 2011-04-05 | Pathak Holdings, Llc | Implantable tissue compositions and method |
| US7351423B2 (en) | 2004-09-01 | 2008-04-01 | Depuy Spine, Inc. | Musculo-skeletal implant having a bioactive gradient |
| US7501486B2 (en) | 2004-09-07 | 2009-03-10 | Burnham Institute For Medical Research | Peptides that selectively home to heart vasculature and related conjugates and methods |
| ATE493444T1 (de) | 2004-10-18 | 2011-01-15 | Nitto Denko Corp | Intrazelluläre peptidabgabe |
| US7507794B2 (en) * | 2005-02-08 | 2009-03-24 | Research Development Foundation | Isolated soluble corticotropin releasing factor receptor type 2 (sCRFR2) |
| US7759120B2 (en) | 2005-03-02 | 2010-07-20 | Kps Bay Medical, Inc. | Seeding implantable medical devices with cells |
| WO2006121532A2 (en) * | 2005-03-31 | 2006-11-16 | Mytogen, Inc. | Treatment for heart disease |
| WO2007012191A1 (en) | 2005-07-27 | 2007-02-01 | Protiva Biotherapeutics, Inc. | Systems and methods for manufacturing liposomes |
| US20070265221A1 (en) | 2006-05-09 | 2007-11-15 | Weiss Robert G | Methods to improve creatine kinase metabolism and contractile function in cardiac muscle for the treatment of heart failure |
| WO2008047241A2 (en) * | 2006-10-16 | 2008-04-24 | Conjuchem Biotechnologies Inc. | Modified corticotropin releasing factor peptides and uses thereof |
| CA2580907A1 (en) | 2006-11-21 | 2008-05-21 | The Bionic Ear Institute | Choroid plexus cell implantation to prevent and/or treat hearing loss |
| US8617534B2 (en) * | 2007-11-16 | 2013-12-31 | San Diego State University (Sdsu) Foundation | Compositions and method for manipulating PIM-1 activity in circulatory system cells |
| CA2711179A1 (en) * | 2007-12-31 | 2009-07-16 | Nanocor Therapeutics, Inc. | Rna interference for the treatment of heart failure |
| JP5651586B2 (ja) * | 2008-05-16 | 2015-01-14 | コーセラ，インコーポレーテッド | 急性心不全に伴う呼吸困難のリラキシンによる治療 |
| MX336145B (es) * | 2008-05-16 | 2016-01-08 | Corthera Inc | Metodo para el tratamiento de insuficiencia cardiaca cronica. |
| US10040838B2 (en) * | 2008-11-04 | 2018-08-07 | Janssen Pharmaceutica Nv | CRHR2 peptide agonists and uses thereof |
| US8734809B2 (en) * | 2009-05-28 | 2014-05-27 | University Of Massachusetts | AAV's and uses thereof |
| WO2011057027A2 (en) * | 2009-11-04 | 2011-05-12 | Janssen Pharmaceutica Nv | Method for treating heart failure with stresscopin-like peptides |
| EP2814513B1 (en) * | 2012-02-14 | 2017-12-20 | The Regents of The University of California | Systemic delivery and regulated expression of paracrine genes for cardiovascular diseases and other conditions |
| US11065347B2 (en) * | 2016-01-19 | 2021-07-20 | The Regents Of The University Of California | Methods for the treatment of Danon disease and other disorders of autophagy |
-
2013
- 2013-02-13 EP EP13749674.1A patent/EP2814513B1/en active Active
- 2013-02-13 KR KR1020147025540A patent/KR102107482B1/ko active Active
- 2013-02-13 DK DK13749674.1T patent/DK2814513T3/en active
- 2013-02-13 EP EP17208610.0A patent/EP3311830A1/en not_active Withdrawn
- 2013-02-13 RU RU2014137169A patent/RU2642605C2/ru active
- 2013-02-13 US US14/378,645 patent/US20150118287A1/en not_active Abandoned
- 2013-02-13 ES ES13749674.1T patent/ES2660492T3/es active Active
- 2013-02-13 CN CN201380019909.5A patent/CN104220098B/zh active Active
- 2013-02-13 HU HUE13749674A patent/HUE036640T2/hu unknown
- 2013-02-13 CA CA2864100A patent/CA2864100A1/en not_active Abandoned
- 2013-02-13 PL PL13749674T patent/PL2814513T3/pl unknown
- 2013-02-13 IN IN6789DEN2014 patent/IN2014DN06789A/en unknown
- 2013-02-13 JP JP2014556826A patent/JP6562632B2/ja active Active
- 2013-02-13 PT PT137496741T patent/PT2814513T/pt unknown
- 2013-02-13 WO PCT/US2013/025997 patent/WO2013123094A2/en not_active Ceased
- 2013-02-13 AU AU2013221615A patent/AU2013221615B2/en active Active
- 2013-02-13 CN CN201810214134.1A patent/CN108310396B/zh active Active
- 2013-02-13 BR BR112014020127-7A patent/BR112014020127A2/pt not_active Application Discontinuation
-
2014
- 2014-08-07 IL IL234007A patent/IL234007A0/en unknown
-
2017
- 2017-06-16 US US15/625,719 patent/US10202618B2/en active Active
- 2017-08-28 JP JP2017163244A patent/JP2017203048A/ja active Pending
-
2018
- 2018-01-31 AU AU2018200719A patent/AU2018200719B2/en active Active
- 2018-08-15 IL IL261172A patent/IL261172A/en unknown
- 2018-10-24 HK HK18113606.9A patent/HK1254639A1/en unknown
- 2018-10-25 IL IL26260018A patent/IL262600B/en active IP Right Grant
- 2018-12-27 US US16/233,970 patent/US10918738B2/en active Active
-
2019
- 2019-05-23 JP JP2019096752A patent/JP2019135263A/ja not_active Withdrawn
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2015508760A5 (enExample) | ||
| RU2014137169A (ru) | Системная доставка и регулируемая экспрессия паракринных генов для лечения сердечно-сосудистых и иных заболеваний | |
| Li | Electroporation gene therapy: new developments in vivo and in vitro | |
| JP2013501816A5 (enExample) | ||
| JP2016521708A5 (enExample) | ||
| JP2020073536A5 (enExample) | ||
| US20240002462A1 (en) | Treatment of neuropathy with igf-1-encoding dna constructs and hgf-encoding dna constructs | |
| JP2017523239A5 (enExample) | ||
| JP2021533126A (ja) | 臓器機能を制御するための遺伝子治療方法 | |
| MX2013008948A (es) | Métodos y composiciones para incrementar la producción de ácido siálico y tratar condiciones de enfermedades relacionadas siálicas. | |
| RU2015155831A (ru) | Аденилатциклаза, некомпетентная по циклическому аденозин монофосфату, композиция и способы для лечения сердечной недостаточности и улучшения сердечной функции | |
| KR20080036015A (ko) | 글루코오스 유도성 인슐린 발현 및 당뇨병 치료 방법 | |
| JP2022060514A (ja) | ガバペンチノイドからの干渉が減少し、ｈｇｆ異型体を発現するｄｎａコンストラクトを用いる神経病症の治療 | |
| JP7413629B2 (ja) | Ｉｇｆ－１異型体を発現させるｄｎａコンストラクトを用いた神経病症の治療 | |
| Ratanamart et al. | Plasmid-mediated muscle-targeted gene therapy for circulating therapeutic protein replacement: a tale of the tortoise and the hare? | |
| CN115804853A (zh) | 包含rna分子的组合物及其在制备瘤内注射剂中的用途 | |
| JP2019031511A (ja) | 低酸素誘導因子−１アルファを有する組成物および当該組成物を用いる方法 | |
| US10130667B1 (en) | TAA/ecdCD40L oncolytic virus | |
| US8481504B2 (en) | Insulin-like growth factor (IGF-I) plasmid-mediated supplementation for therapeutic applications | |
| Adjmi | Cardiomyocyte-Specific Delivery of hPKM2 modRNA via CM-SMRTs Drives Regeneration and Functional Recovery in a Porcine Model of Myocardial Infarction | |
| CN100372572C (zh) | 携带人胸腺素β4基因的重组质粒 | |
| WO2024072820A1 (en) | Compositions and methods for modulating t cell function | |
| Di Pasquale et al. | 656. Transduction of Non-Human Primate Retina with Intravitreally Administered AAV Vectors of Different Serotypes: Investigations into In. ammation and Possibility of Treatment of Contralateral Eye | |
| Grimstein et al. | 343. Endothelial Cell-Specific Rescue of Tie2 Angiopoietin Receptor in Tie2-Null Mice by microRNA-Regulated Lentiviral Vector Suggests a Requisite Role for Tie2 in the Hematopoietic System | |
| HK1257863A1 (en) | Systemic delivery and regulated expression of paracrine genes for cardiovascular diseases and other conditions |